Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17195403 | 0.84 | MAPT (0.55) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL4863619 | 0.81 | MAPT (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL4863177 | 0.81 | MAPT (0.59) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL9852004 | 0.81 | MAPT (0.55) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL11300549 | 0.77 | CA1 (0.48) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL11518048 | 0.77 | MAPT (0.80) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL9100229 | 0.77 | MAPT (0.59) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL7149998 | 0.76 | MAPT (0.71) | MAPTALDH1A1GAAPRSS1F2 | |
| SCHEMBL5945705 | 0.76 | CA1 (0.55) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL18361699 | 0.75 | CA1 (0.73) | MAPTCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101412709-B | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARM LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2008-11-13 | — | — | US | disclosed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | disclosed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | RIN1, ZC3HAV1L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPT 4756/4885CA1 3679/4885CA2 336/4885 |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3 | MAPT 4694/4885CA1 4120/4885CA2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.